Abstract
Some recent results in treatment options in non small-cell lung cancer (NSCLC) and renal cancer (RC) are presented. Both - targeted and combined imunooncologic therapy are effective in therapy of NSCLC and RC patients.
In NSCLC, also combination of imunooncologic drugs with systemic chemotherapy should be recommended.